中源协和：全资子公司获得VUM02注射液药物临床试验批准通知书

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia, marking a significant advancement in the company's product pipeline [1] Company Summary - VUM02 injection is a cryopreserved cell preparation independently developed by Zhongyuan Union, with the clinical indication expanding to include the treatment of severe/critical pneumonia [1] - As of the announcement date, there are no similar cell drugs approved for the treatment of severe/critical pneumonia globally, with the fastest progressing similar drugs still in clinical trial stages [1]